NCT01920191View on ClinicalTrials.gov

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
CNS Tumor, Adult
Interventions
BIOLOGICAL

IMA 950

BIOLOGICAL

Poly ICLC

OTHER

Immunomonitoring

Blood samples, DTH analysis

Trial Locations (1)

CH-1211

Geneva University Hospitals, Centre of Oncology, Geneva

Sponsors
All Listed Sponsors
collaborator

Immatics Biotechnologies GmbH

INDUSTRY

collaborator

Oncovir, Inc.

INDUSTRY

lead

University Hospital, Geneva

OTHER